Compare Chugai Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 23.71%
- Healthy long term growth as Net Sales has grown by an annual rate of 9.84% and Operating profit at 15.41%
- Company has very low debt and has enough cash to service the debt requirements
2
The company has declared Positive results for the last 4 consecutive quarters
3
With ROE of 22.71%, it has a very attractive valuation with a 7.45 Price to Book Value
4
Majority shareholders : Non Institution
Stock DNA
Pharmaceuticals & Biotechnology
JPY 13,591,972 Million (Large Cap)
33.00
NA
0.02%
-0.45
25.14%
7.12
Revenue and Profits:
Net Sales:
321,747 Million
(Quarterly Results - Mar 2026)
Net Profit:
115,418 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.22%
0%
-8.22%
6 Months
5.78%
0%
5.78%
1 Year
-4.96%
0%
-4.96%
2 Years
60.37%
0%
60.37%
3 Years
120.18%
0%
120.18%
4 Years
105.52%
0%
105.52%
5 Years
92.21%
0%
92.21%
Chugai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.84%
EBIT Growth (5y)
15.41%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
0.64
Tax Ratio
29.16%
Dividend Payout Ratio
103.14%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
52.96%
ROE (avg)
23.71%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
7.45
EV to EBIT
22.48
EV to EBITDA
21.26
EV to Capital Employed
13.49
EV to Sales
11.22
PEG Ratio
1.86
Dividend Yield
0.02%
ROCE (Latest)
60.01%
ROE (Latest)
22.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
321,747.00
346,301.00
-7.09%
Operating Profit (PBDIT) excl Other Income
171,469.00
181,311.00
-5.43%
Interest
0.00
95.00
-100.00%
Exceptional Items
-4,500.00
0.00
Consolidate Net Profit
115,418.00
128,410.00
-10.12%
Operating Profit Margin (Excl OI)
505.60%
489.20%
1.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.09% vs 3.94% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -10.12% vs 15.46% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,257,941.00
1,170,611.00
7.46%
Operating Profit (PBDIT) excl Other Income
624,442.00
575,572.00
8.49%
Interest
433.00
95.00
355.79%
Exceptional Items
-27,566.00
-8,992.00
-206.56%
Consolidate Net Profit
434,012.00
387,317.00
12.06%
Operating Profit Margin (Excl OI)
470.50%
464.60%
0.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.46% vs 5.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.06% vs 19.00% in Dec 2024
About Chugai Pharmaceutical Co., Ltd. 
Chugai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






